State Street’s Hemab Therapeutics COAG Stock Holding History

State Street’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$28.6M	Buy	927,245 +850,345	+1,106%	+$37.3M	﹤0.01%	2134
2026 Q2	$2.82M	Buy	+76,900	New	+$2.12M	﹤0.01%	3273

Other funds holding COAG

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

State Street's COAG Position: Q3 2026 in Review

State Street increased its Hemab Therapeutics (COAG) stake by 1,106% in Q3 2026, buying an estimated $37.3M and bringing the position to 927,245 shares worth $28.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

State Street first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

State Street held 927,245 shares of Hemab Therapeutics worth $28.6M as of Q3 2026.
State Street bought 850,345 Hemab Therapeutics shares in Q3 2026, an estimated $37.3M.
Hemab Therapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #2134 holding.
State Street first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
49 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.